Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A host of studies have revealed that long non-coding RNAs (lncRNAs) are critically involved in the development and progression of epithelial ovarian cancer. LncRNA
TUBA4B
is recently identified to be a critical mediator in non-small cell lung cancer. However, the clinical roles and biological functions of lncRNA
TUBA4B
in epithelial ovarian cancer have yet to be fully clarified. The present study was conducted to explore the expression of lncRNA
TUBA4B
in human epithelial ovarian cancer tissues and potential roles of lncRNA
TUBA4B
in ovarian cancer cells. The matched epithelial ovarian cancer specimens and adjacent normal tissues were employed to detect the expression of lncRNA
TUBA4B
. The prognostic value of lncRNA
TUBA4B
for tumor progression and survival rate was investigated. The effects of lncRNA
TUBA4B
on ovarian cancer cell proliferation and migration were also explored. The expression of lncRNA
TUBA4B
was significantly decreased in epithelial ovarian cancer tissue specimens. The low lncRNA
TUBA4B
level was closely related with pathological grade, FIGO stage and lymph node
metastases
, and serum CA125 level. Enforced expression of lncRNA
TUBA4B
obviously reduced the proliferation of SKOV3 cells, and attenuated the activation of ERK and Akt signaling pathways. Our data demonstrate for the first time that lower lncRNA
TUBA4B
may be a novel independent prognostic biomarker for overall survival of epithelial ovarian cancer. Overexpression of lncRNA
TUBA4B
inhibits the proliferation of ovarian cancer cells. LncRNA
TUBA4B
may be an important target for therapeutic intervention in ovarian cancer.
...
PMID:Downregulation of lncRNA TUBA4B is Associated with Poor Prognosis for Epithelial Ovarian Cancer. 2857 89